A randomised, single blind, 2 period, crossover study to compare the single dose pharmacokinetics and tolerability of formulations containing unmilled and micronised SB-568859 [GSK-568859] in healthy adults.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs GSK 568859 (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- 10 Nov 2007 Status changed from recruiting to completed.
- 11 Jul 2007 New trial record.